Galapagos Hit By Atopic Dermatitis Drug Fail
End For IL-7C Inhibitor Partnered With MorphoSys And Novartis
Executive Summary
The fundamentals for Galapagos are sound despite the failure of MOR106 for atopic dermatitis and two trials of filgotinib missing their primary endpoints for Sjögren’s syndrome and lupus.
You may also be interested in...
AbbVie’s Post-Humira Strategy Continues Taking Shape With Rinvoq Approval
AbbVie now has both of its Humira successors approved in the US, following April’s Skyrizi approval for psoriasis. But Rinvoq faces stiff competition both within the JAK1 class and in rheumatoid arthritis generally.
$5bn Galapagos Deal Won’t Be Last For Gilead, Says O’Day
Handing over $5bn to Galapagos for access to several shots on the inflammation/fibrosis goal, Gilead Sciences CEO Daniel O’Day is still on the prowl for more.
Partner Or Go It Alone? TG Therapeutics Ponders EU Plans For Briumvi
TG Therapeutics has successfully launched Briumvi on its own in the US, despite fierce competition from established same-class MS drugs Ocrevus and Kesimpta, but is still weighing up the pros and cons of partnering for the European market.